Despite considerable efforts to identify cancer metabolic alterations that might unveil druggable vulnerabilities, systematic characterizations of metabolism as it relates to functional genomic features and associated dependencies remain uncommon. To further understand the metabolic diversity of cancer, we profiled 225 metabolites in 928 cell lines from more than 20 cancer types in the Cancer Cell Line Encyclopedia (CCLE) using liquid chromatography–mass spectrometry (LC-MS). This resource enables unbiased association analysis linking the cancer metabolome to genetic alterations, epigenetic features and gene dependencies. Additionally, by screening barcoded cell lines, we demonstrated that aberrant ASNS hypermethylation sensitizes subsets of gastric and hepatic cancers to asparaginase therapy. Finally, our analysis revealed distinct synthesis and secretion patterns of kynurenine, an immune-suppressive metabolite, in model cancer cell lines. Together, these findings and related methodology provide comprehensive resources that will help clarify the landscape of cancer metabolism.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
The CCLE metabolomic data and related analyses can be found in Supplementary Tables 1–4. Additional CCLE resources are available at: https://portals.broadinstitute.org/ccle. Source data of all western blots and DNA gels in this work are provided in Source Data Figures.
Vander Heiden, M. G. et al. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029–1034 (2009).
Pavlova, N. N. & Thompson, C. B. The emerging hallmarks of cancer metabolism. Cell. Metab. 23, 27–47 (2016).
Cairns, R. A., Harris, I. S. & Mak, T. W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 11, 85–95 (2011).
Vander Heiden, M. G. & Deberardinis, R. J. Understanding the intersections between metabolism and cancer biology. Cell 168, 657–669 (2017).
Tennant, D. A., Durán, R. V. & Gottlieb, E. Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer 10, 267–277 (2010).
McDonald, E. R. I. et al. Project DRIVE: a compendium of cancer dependencies and synthetic lethal relationships uncovered by large-Scale, deep RNAi screening. Cell 170, 577–592 (2017).
Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012).
Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564–576 (2017).
Ghandi, M. et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature https://doi.org/10.1038/s41586-019-1186-3 (2019).
Xu, W. et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of a ketoglutarate-dependent dioxygenases. Cancer Cell. 19, 17–30 (2011).
Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739–744 (2009).
Shim, E. H. et al. L-2-hydroxyglutarate: An epigenetic modifier and putative oncometabolite in renal cancer. Cancer Discov. 4, 1290–1298 (2014).
Wakabayashi, N. et al. Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. Proc. Natl Acad. Sci. USA 101, 2040–2045 (2004).
Ohta, T. et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res. 68, 1303–1309 (2008).
Dey, P. et al. Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Nature 542, 119–123 (2017).
Meyers, R. M. et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat. Genet. 49, 1779–1784 (2017).
Indiveri, C., Tonazzi, A., Prezioso, G. & Palmieri, F. Kinetic characterization of the reconstituted carnitine carrier from rat liver mitochondria. Biochim. Biophys. Acta 1065, 231–238 (1991).
Yang, W. S. et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317–331 (2014).
Yu, C. et al. High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. Nat. Biotechnol. 34, 419–423 (2016).
Mezrich, J. D. et al. An Interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 185, 3190–3198 (2010).
Uyttenhove, C. et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9, 1269–1274 (2003).
Munn, D. H. & Mellor, A. L. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 34, 137–143 (2013).
Brochez, L., Chevolet, I. & Kruse, V. The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy. Eur. J. Cancer 76, 167–182 (2017).
Jain, M. et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 336, 1040–1044 (2012).
Long, G. V. Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: results of the phase 3 ECHO-301/KEYNOTE-252 study. J. Clin. Oncol. 36, abstr. 108 (2018).
Narta, U. K., Kanwar, S. S. & Azmi, W. Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Crit. Rev. Oncol. Hematol. 61, 208–221 (2007).
Hettmer, S. et al. Functional genomic screening reveals asparagine dependence as a metabolic vulnerability in sarcoma. eLife 4, 1–17 (2015).
Knott, S. R. V. et al. Asparagine bioavailability governs metastasis in a model of breast cancer. Nature 554, 378–381 (2018).
Townsend, M. K. et al. Reproducibility of metabolomic profiles among men and women in 2 large cohort studies. Clin. Chem. 59, 1657–1667 (2013).
The authors would like to thank E. Gelfand for assistance with project management. We acknowledge J. Jane-Valbuena, S. Gill, V. Viswanathan, L. Dailey, and R. Almeida for helpful discussions. The PRISM team including J. Roth, S. Bender, K. Gore, C. Zhu, and J. Fonseka provided valuable help for the pooled CCLE cancer cell line screening at the Broad Institute. We thank Dana-Farber/Harvard Cancer Center in Boston, MA for the use of the Specialized Histopathology Core, which provided histology and immunohistochemistry service. Dana-Farber/Harvard Cancer Center is supported in part by an NCI Cancer Center Support Grant #NIH 5 P30 CA06516. The CCLE project was supported by grants from Novartis and R35 Outstanding Investigator Award from the National Cancer Institute (L.A.G.) and U01 CA176058 (W.C.H.). This work was supported in part by the NCI’s Cancer Target Discovery and Development (CTD2) Network (grant number U01 CA217848, awarded to S.L.S.). H. Li is a fellow in the Herchel Smith graduate fellowship program.
G.V.K. is an employee of and has equity in KSQ Therapeutics. G.V.K. is also a shareholder of Illumina and CRISPR Therapeutics. J.A., D.S., V.A., and G.G.G. are current Novartis employees. J.B. is a shareholder and former employee of Novartis. R.A.P. is a former employee of Novartis and a current employee of Celsius Therapeutics. W.C.H. is a consultant for Thermo-Fisher, Seer, AjuIB, MPM Capital, and KSQ Therapeutics and receives research funding from Deerfield Management. W.C.H. is a founder and has equity in KSQ Therapeutics. L.A.G. is a current employee at Eli Lilly and Company. A.T. is a consultant for Tango Therapeutics. M. Giannakis participated in an advisory board for Astrazeneca and receives research funding from Bristol-Myers Squibb. S.L.S. is a shareholder of Forma Therapeutics, a shareholder of and adviser to Jnana Therapeutics and Decibel Therapeutics, an adviser to Eisai, Inc. and F-Prime Capital Partners, and a Novartis Faculty Scholar. W.R.S. is a shareholder and former employee of Novartis. W.R.S. is a consultant and shareholder for Peloton Therapeutics and Ideaya Biosciences and is a consultant for Array, Astex, Ibsen, Servier, and Sanofi Pharmaceuticals and Epidarex Capital and receives research funding from Deerfield Management. H.L. and W.R.S. have a patent application based on this work. The other authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
a, Metabolites ordered by estimated coefficients of variance (CV). b, Heat map showing the hierarchical clustering of the CCLE metabolomic data with annotated tissues of origin. CNS, central nervous system; UAT, upper aerodigestive tract. For each metabolite (log10 scale), the abundance was standardized for plotting. c, Ordered lineage effects of the 225 profiled metabolites. Each dot represents a metabolite. d, Phosphocreatine levels with medians across the CCLE cell lines grouped by tissues of origin. e, 1-methylnicotinamide levels with medians across the CCLE cell lines grouped by tissues of origin.
a, Reduced glutathione (GSH) levels and the top correlated mutations among all mutational features. Cell lines are shown as lines and ordered by increasing levels of GSH. Cell lines with corresponding mutations are labeled in black. The reported test statistics and P values are based on the significance tests of genetic feature regression coefficients (cell line n = 927, two-sided t tests). b, Swarm plot comparing GSH, GSSG, and NADP+ levels in cell lines with or without KEAP1 mutations (n = 72 and 855, respectively, mean ± s.d.). Each dot represents a cell line. The P values were calculated based on two-sample t tests (two-sided). c–h, Volcano plots comparing 225 profiled metabolites based on the mutational status of EGFR (c), KRAS (d), NRAS (e), TP53 (f), PTEN (g), and TSC1/2 (h) in CCLE cell lines. Each point represents a metabolite and the red lines indicate a cutoff of q = 0.05. The statistical significance and effect sizes were calculated using linear regression models conditioned on major lineage types (two-sided t test). Note that cell lines with either PTEN mutation or deletion were defined as PTEN deficient. i, Scatter plot comparing ME2 copy number alterations with its mRNA levels in all cell lines. j, Scatter plot comparing ME2 mRNA levels with malate levels in all cell lines. k, Scatter plot comparing ME2 mRNA levels with ME3-knockout CERES scores. For i–k, the P values were calculated based on the significance test of Pearson correlations (two-sided). The number of cell lines used for analysis is shown above each plot.
a–j, Scatter plots comparing SLC25A20 mRNA transcripts with different metabolites: carnitine (a), acetylcarnitine (b), propionylcarnitine (c), malonylcarnitine (d), butyrylcarnitine/isobutyrylcarnitine (e), valerylcarnitine/isovalerylcarnitine/2-methylbutyroylcarnitine (f), hexanoylcarnitine (g), heptanoylcarnitine (h), lauroylcarnitine (i), arachidonylcarnitine (j). The q values were calculated based on significance test of Pearson correlations (two-sided) with multiple hypothesis testing correction.
a, Cropped immunoblot of ASNS in A2058 cells with or without dox-inducible ASNS knockdown (KD). Tubulin was used as the loading control. The experiment was repeated twice independently with similar results. b, Relative cell growth upon ASNS KD with or without rescue in the A2058 cell line grown in DMEM without asparagine (mean ± s.e.m., n = 2 cell culture replicates, two-sample t test, two-sided). After 13 d, the relative growth was quantified by standard crystal violet staining. PLK1 KD was used as a control. NEAA, non-essential amino acids. c, ASNS mRNA levels with medians across the CCLE lines grouped by cancer type. DLBCL, diffuse large B-cell lymphoma; CML, chronic myeloid leukemia; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia. d, Scatter plot comparing ATF4 mRNA levels with ASNS mRNA levels in all cell lines. e, Schematic depicting part of the metabolic pathway of asparagine, arginine, and glutamine. f, Scatter plot comparing ASS1 DNA methylation levels with ASS1 mRNA levels in all cell lines. g, Scatter plot comparing GLUL DNA methylation levels with GLUL mRNA levels in all cell lines. For f,g, the P values were calculated based on the significance test of Pearson correlations (two-sided). The number of cell lines used for analysis is shown in the plot above. h, Waterfall plot showing the fold changes of pooled CCLE lines (n = 554, median of three independent cell culture replicates) cultured in RPMI medium containing 0.1 µM glutamine for 6 d (normalized to control). The colors show the associated cell doubling time. For h, the P value was calculated based on the significance test of Pearson correlations (two-sided). Source data
a, Surgically removed SNU719 tumors after asparaginase treatment or vehicle control treatment (two tumors per nude mouse). b, Relative mouse body weight changes in the duration of asparaginase treatment (3,000 units/kg, 5×/week) or vehicle control (n = 5 nude mice per condition, mean ± s.e.m.). c, Methylation-specific PCR for ASNS CpG islands in different tumor samples (a cropped gel image is shown). This experiment was repeated once. d, Bisulfite sequencing for ASNS methylation status in different tumor samples. Open circles indicate unmethylated CpG, and solid circles indicate methylated CpG. This experiment was repeated once with four technical replicates for each different tumor sample. Source data
a, Waterfall plots showing the fold changes of pooled CCLE lines (n = 554, median of three independent cell culture replicates) cultured in RPMI media containing 10 µM or 100 µM kynurenine for 6 d (normalized to control). The colors show the associated kynurenine levels in cells. The P values were calculated based on the significance test of Pearson correlations (two-sided). b, Schematic depicting part of the tryptophan catabolism pathway. c, Kynurenine levels and a heat map representation of top correlated mRNA transcripts in each cell line. The feature values (log2 RPKM) were standardized for plotting. The reported test statistics and P values are based on the significance tests of mRNA feature regression coefficients (cell line n = 913, two-sided t tests). d, mRNA levels of IDO1 and/or IDO2 correlate with kynurenine accumulation (Pearson correlation = 0.26 and 0.22, respectively; two-sided P < 1 × 10−15 and P = 2.5 × 10−11, respectively). Cell lines (n = 913) are represented as points with color-coded kynurenine levels.
About this article
Cite this article
Li, H., Ning, S., Ghandi, M. et al. The landscape of cancer cell line metabolism. Nat Med 25, 850–860 (2019). https://doi.org/10.1038/s41591-019-0404-8
Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets
Cell Metabolism (2021)
Molecular Omics (2021)
Shedding Light on the African Enigma: In Vitro Testing of Homo sapiens-Helicobacter pylori Coevolution
Pseudomonas aeruginosa recombinant L-asparaginase: Large scale production, purification, and cytotoxicity on THP-1, MDA-MB-231, A549, Caco2 and HCT-116 cell lines
Protein Expression and Purification (2021)
Differential Gene Set Enrichment Analysis: a statistical approach to quantify the relative enrichment of two gene sets